Aisling Capital buys $105,517,415 stake in Loxo Oncology Inc (LOXO)

Loxo Oncology Inc (LOXO) : Aisling Capital scooped up 232,558 additional shares in Loxo Oncology Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 4,028,920 shares of Loxo Oncology Inc which is valued at $105,517,415.Loxo Oncology Inc makes up approximately 22.61% of Aisling Capital’s portfolio.

Other Hedge Funds, Including , Parametric Portfolio Associates boosted its stake in LOXO in the latest quarter, The investment management firm added 3,222 additional shares and now holds a total of 16,457 shares of Loxo Oncology Inc which is valued at $431,009.Tower Research Capital (trc) reduced its stake in LOXO by selling 100 shares or 50.0% in the most recent quarter. The Hedge Fund company now holds 100 shares of LOXO which is valued at $2,619.New York State Common Retirement Fund boosted its stake in LOXO in the latest quarter, The investment management firm added 523 additional shares and now holds a total of 14,473 shares of Loxo Oncology Inc which is valued at $379,048.Vanguard Group Inc boosted its stake in LOXO in the latest quarter, The investment management firm added 221,901 additional shares and now holds a total of 499,283 shares of Loxo Oncology Inc which is valued at $13,076,222.Blackrock Advisors boosted its stake in LOXO in the latest quarter, The investment management firm added 1,061 additional shares and now holds a total of 5,213 shares of Loxo Oncology Inc which is valued at $136,528.

Loxo Oncology Inc opened for trading at $26.69 and hit $27.21 on the upside on Monday, eventually ending the session at $27.07, with a gain of 1.61% or 0.43 points. The heightened volatility saw the trading volume jump to 91,610 shares. Company has a market cap of $586 M.

Loxo Oncology Inc. is engaged in discovery development and commercialization of targeted cancer therapies. LOXO-101 is the Company’s lead product and has completed its pre-clinical research. LOXO-101 is an oral selective inhibitor of the tropomyosin receptor kinase (TRK) family. The Company is developing it for the treatment of tumors with TRK alterations. TRK has been implicated in various tumor types such as lung cancer head and neck cancer melanoma colorectal cancer sarcoma and breast cancer. The Company is conducting Phase 1 clinical trial of LOXO-101 which is an open label multicenter trial and has two stages: dose escalation and expansion. The objectives of the dose escalation stage are to determine the tolerated dose and the appropriate dose for further clinical investigation as well as to determine the tolerability and pharmacokinetic profile of orally administered LOXO-101.

Leave a Reply

Loxo Oncology Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Loxo Oncology Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.